UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cost Structures of US Organ Procurement Organizations

Transplantation, 2021-12, Vol.105 (12), p.2612-2619

2021

Volltextzugriff (PDF)

The Cost of Procuring Deceased Donor Livers: Evidence From US Organ Procurement Organization Cost Reports, 2013–2018

Clinical transplantation, 2024-09, Vol.38 (9), p.e15452-n/a

2024

Volltextzugriff (PDF)

Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients

Supportive care in cancer, 2012-07, Vol.20 (7), p.1405-1415

2012

Volltextzugriff (PDF)

Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer

Cancer research (Chicago, Ill.), 2009-05, Vol.69 (10), p.4184-4191

2009

Volltextzugriff (PDF)

Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study

Breast cancer research : BCR, 2010-01, Vol.12 (3), p.R26-R26, Article R26

2010

Volltextzugriff (PDF)

Conventional Adjuvant Chemotherapy with or without High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in High-Risk Breast Cancer

The New England journal of medicine, 2003-07, Vol.349 (1), p.17-26

2003

Volltextzugriff (PDF)

Fatal sickle cell crisis after granulocyte colony-stimulating factor administration

Blood, 2001-05, Vol.97 (10), p.3313-3314

2001

Volltextzugriff (PDF)

The long road to a cure for acute myelocytic leukemia: from intensity to specificity

Journal of clinical oncology, 2008-07, Vol.26 (21), p.3475-3477

2008

Volltextzugriff (PDF)

Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen

Biology of blood and marrow transplantation, 2006-07, Vol.12 (7), p.770-777

2006

Volltextzugriff (PDF)

Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer

JAMA : the journal of the American Medical Association, 1999-10, Vol.282 (14), p.1335

1999

Volltextzugriff (PDF)

Long-term follow-up of a 10-year single-center experience with high-dose pharmacokinetics-directed intravenous busulfan in combination with cyclophosphamide and etoposide as preparative regimen for intermediate- and high-grade non-Hodgkin lymphoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e19521-e19521

2014

Volltextzugriff (PDF)

Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation

Clinical advances in hematology & oncology, 2007-11, Vol.5 (11), p.882

2007

Volltextzugriff (PDF)

Benchmarks in Clinical Productivity: A National Comprehensive Cancer Network Survey

Journal of oncology practice, 2007-01, Vol.3 (1), p.2-8

2007

Volltextzugriff (PDF)

Hickman catheter‐induced thoracic vein thrombosis. Frequency and long‐term sequelae in patients receiving high‐dose chemotherapy and marrow transplantation

Cancer, 1990-09, Vol.66 (5), p.900-908

1990

Volltextzugriff (PDF)

Effective Chemotherapy of Acute Myelocytic Leukemia Occurring After Alkylating Agent or Radiation Therapy for Prior Malignancy

Journal of clinical oncology, 2008, Vol.26 (21)

2008

Volltextzugriff (PDF)

A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan

Biology of blood and marrow transplantation, 2002-01, Vol.8 (11), p.619-624

2002

Volltextzugriff (PDF)

Improving Dosing Precision in Buslfan (BU) Based Preparative Regimens for Hematopoietic Stem Cell Transplantation (HSCT)

Blood, 2004-11, Vol.104 (11), p.1148-1148

2004

Volltextzugriff (PDF)

Pulmonary Surveillance Using Bronchoscopy and Bronchoalveolar Lavage during High-Dose Antineoplastic Therapy

Chest, 1991-01, Vol.99 (1), p.105-111

1991

Volltextzugriff (PDF)

Use of Dexamethasone Given to Sibling Donors as a Way of In Vivo Purging of Allo Reactive Donor T Cells in rhg-CSF Mobilized Peripheral Blood Stem Cell Transplantations Resulted in Significant Decrease in CD3+ Cells and Increased CD34+ Yield

Blood, 2007-11, Vol.110 (11), p.3047-3047

2007

Volltextzugriff (PDF)

ASBMT Risk Group and CD 34+ Dose Predicted for the Development of aGVHD in Allogeneic MRD Transplants When the Donors Who Received a Combined Mobilization and In Vivo TCD Regimen Using rhg-CFS and Dexamethasone

Blood, 2007-11, Vol.110 (11), p.5006-5006

2007

Volltextzugriff (PDF)

Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit

Biology of blood and marrow transplantation, 2003-11, Vol.9 (11), p.722-724

2003

Volltextzugriff (PDF)

Infiltrating ductal carcinoma of the breast: the survival impact of race

Journal of clinical oncology, 1998-08, Vol.16 (8), p.2693-2699

1998

Volltextzugriff (PDF)

Improved Outcomes of Autologous (Auto) Hematopoeitic Stem Cell Transplantation (HSCT) for Intermediate and High Risk (I/HR) Aggressive (AG) Non Hodgkin Lymphoma (NHL) with IV vs PO Busulfan (Bu) in a Bu, Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen

Blood, 2004-11, Vol.104 (11), p.1881-1881

2004

Volltextzugriff (PDF)

Decreased Acute but Not Chronic Graft Versus Host Disease (GVHD) after Allogeneic (ALLO) Hematopoietic Stem Cell Transplant (HSCT) from Matched Sibling Donors (MRD) Using Peripheral Blood Progenitor Cells (PBPC) Mobilized with Filgastrim (GCSF) Plus Dexamethasone (DEX)

Blood, 2004-11, Vol.104 (11), p.3342-3342

2004

Volltextzugriff (PDF)

Descriptive Analysis of Changing Toxicity Profiles for 30- and 100-Day Mortality After Matched Related Donor (MRD) Allogeneic (ALLO) Hematopoietic Stem Cell Transplantation (HSCT) Using PO- Versus IV Busulfan (BU)-Based Conditioning Regimens: ONC-2

Southern medical journal (Birmingham, Ala.), 2005-10, Vol.98 (Supplement), p.S73

2005

Volltextzugriff (PDF)

1 – 25 von 336

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(270)
Mit Volltextzugriff
(282)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(335)
Deutsch
(1)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Cost Structures of US Organ Procurement Organizations

The Cost of Procuring Deceased Donor Livers: Evidence From US Organ Procurement Organization Cost Reports, 2013–2018

Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients

Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer

Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study

Conventional Adjuvant Chemotherapy with or without High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in High-Risk Breast Cancer

Fatal sickle cell crisis after granulocyte colony-stimulating factor administration

The long road to a cure for acute myelocytic leukemia: from intensity to specificity

Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen

Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer

Long-term follow-up of a 10-year single-center experience with high-dose pharmacokinetics-directed intravenous busulfan in combination with cyclophosphamide and etoposide as preparative regimen for intermediate- and high-grade non-Hodgkin lymphoma

Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation

Benchmarks in Clinical Productivity: A National Comprehensive Cancer Network Survey

Hickman catheter‐induced thoracic vein thrombosis. Frequency and long‐term sequelae in patients receiving high‐dose chemotherapy and marrow transplantation

Effective Chemotherapy of Acute Myelocytic Leukemia Occurring After Alkylating Agent or Radiation Therapy for Prior Malignancy

A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan

Improving Dosing Precision in Buslfan (BU) Based Preparative Regimens for Hematopoietic Stem Cell Transplantation (HSCT)

Pulmonary Surveillance Using Bronchoscopy and Bronchoalveolar Lavage during High-Dose Antineoplastic Therapy

Use of Dexamethasone Given to Sibling Donors as a Way of In Vivo Purging of Allo Reactive Donor T Cells in rhg-CSF Mobilized Peripheral Blood Stem Cell Transplantations Resulted in Significant Decrease in CD3+ Cells and Increased CD34+ Yield

ASBMT Risk Group and CD 34+ Dose Predicted for the Development of aGVHD in Allogeneic MRD Transplants When the Donors Who Received a Combined Mobilization and In Vivo TCD Regimen Using rhg-CFS and Dexamethasone

Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit

Infiltrating ductal carcinoma of the breast: the survival impact of race

Improved Outcomes of Autologous (Auto) Hematopoeitic Stem Cell Transplantation (HSCT) for Intermediate and High Risk (I/HR) Aggressive (AG) Non Hodgkin Lymphoma (NHL) with IV vs PO Busulfan (Bu) in a Bu, Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen

Decreased Acute but Not Chronic Graft Versus Host Disease (GVHD) after Allogeneic (ALLO) Hematopoietic Stem Cell Transplant (HSCT) from Matched Sibling Donors (MRD) Using Peripheral Blood Progenitor Cells (PBPC) Mobilized with Filgastrim (GCSF) Plus Dexamethasone (DEX)

Descriptive Analysis of Changing Toxicity Profiles for 30- and 100-Day Mortality After Matched Related Donor (MRD) Allogeneic (ALLO) Hematopoietic Stem Cell Transplantation (HSCT) Using PO- Versus IV Busulfan (BU)-Based Conditioning Regimens: ONC-2

Suchergebnisse filtern